Skip to main content

Cynomolgus Monkey LAG-3 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB10395

Recombinant Monoclonal Antibody.
R&D Systems, part of Bio-Techne

Key Product Details

Species Reactivity

Cynomolgus Monkey

Applications

CyTOF-ready, Flow Cytometry

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # 2561B

Product Specifications

Immunogen

Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey LAG-3
Val20-Leu450
Accession # XP_005570011.1

Specificity

Detects cynomolgus monkey LAG-3 in direct ELISAs.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for Cynomolgus Monkey LAG-3 Antibody

Detection of LAG-3 antibody in HEK293 Human Cell Line Transfected with Cynomolgus Monkey LAG-3 and eGFP antibody by Flow Cytometry.

Detection of LAG-3 in HEK293 Human Cell Line Transfected with Cynomolgus Monkey LAG-3 and eGFP by Flow Cytometry.

HEK293 human embryonic kidney cell line transfected with (A) cynomolgus monkey LAG-3 or (B) irrelevant protein and eGFP was stained with Rabbit Anti-Cynomolgus Monkey LAG-3 Monoclonal Antibody (Catalog # MAB10395) followed by APC-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # F0111). Quadrant markers were set based on control antibody staining (Catalog # MAB1050). View our protocol for Staining Membrane-associated Proteins.

Applications for Cynomolgus Monkey LAG-3 Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/106 cells
Sample: HEK293 Human Cell Line Transfected with Cynomolgus Monkey LAG-3 and eGFP

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LAG-3

LAG-3 (Lymphocyte activation gene-3), designated CD223, is a type I transmembrane protein that is a member of the immunoglobulin superfamily (IgSF) (1, 2). LAG ‑ 3 shares approximately 20% amino acid (aa) sequence homology with CD4, but has similar structure and binds to MHC class II with higher affinity, providing negative regulation of T cell receptor signaling (1, 2). The mature cynomolgus LAG-3 includes an extracellular domain (ECD) with four Ig-like domains, a transmembrane region and a highly charged cytoplasmic region. Within the ECD, cynomolgus LAG-3 shares 92%, 69% and 68% aa sequence identity with human, mouse and rat LAG-3, respectively. LAG-3 is expressed on activated CD4+ and CD8+ T cells, NK cells, and plasmacytoid dendritic cells (pDC), but not on resting T cells (1-3). LAG-3 on activated CD4+CD25+ Treg cells plays a role in their suppressive activity (4). LAG-3 limits the expansion of activated T cells and pDC in response to selected stimuli (3-5). A soluble 54 kDa form, sLAG-3, can be shed by metalloproteinases ADAM10 and TACE/ADAM17 (6, 7). While monomeric sLAG-3 itself may be inactive, shedding allows for normal T cell activation by removing negative regulation (7). Binding of sLAG-3 to MHC class II molecules induces maturation of immature DC, and secretion of cytokines such as IFN-gamma and TNF-alpha by type 1 cytotoxic CD8+ T cells and NK cells (8, 9). sLAG-3 has been used as a potential adjuvant to stimulate a cytotoxic anti-cancer immune response (9, 10). In mice, deletion of LAG-3 and another negative regulator, PD-1, facilitates anti-cancer response but also blocks self-tolerance and increases susceptibility to autoimmune diseases (11, 12). In humans, antibody-mediated down‑regulation of LAG-3 and PD-1 allows more effective control of chronic malaria, while in NOD (non‑obese diabetic) mice, deletion of LAG-3 alone accelerates diabetes (12-14). In addition, LAG-3 is an immune checkpoint protein that modulates T-cell activation and homeostasis and is a promising target for cancer immunotherapies (15, 16).

References

  1. Triebel, F. et al. (1990) J. Exp. Med. 171:1393.
  2. Baixeras, E. et al. (1992) J. Exp. Med 176:327.
  3. Workman, C.J. et al. (2004) J. Immunol. 172:5450.
  4. Huang, C.T. et al. (2004) Immunity 21:503.
  5. Workman, C.J. et al. (2009) J. Immunol. 182:1885.
  6. Li, N. et al. (2004) J. Immunol. 173:6806.
  7. Li, N. et al. (2007) EMBO J. 26:494.
  8. Andreae, S. et al. (2003) Blood 102:2130.
  9. Brignone, C. et al. (2007) J. Immunol. 179:4202.
  10. Brignone, C. et al. (2010) J. Transl. Med. 8:71.
  11. Woo, S.R. et al. (2011) Cancer Res. 72:917.
  12. Okazaki, T. et al. (2011) J. Exp. Med. 208:395.
  13. Bettini, M. et al. (2011) J. Immunol. 187:3493.
  14. Butler, N.S. et al. (2012) Nat. Immunol. 13:188.
  15. Durham N.M. et al. (2014) PLoS One. 9:e109080.
  16. Deng W.W. et al. (2016) Oncoimmunology. 5:e1239005

Long Name

Lymphocyte-activation Gene 3

Alternate Names

CD223, LAG3

Entrez Gene IDs

3902 (Human); 16768 (Mouse); 297596 (Rat); 102122272 (Cynomolgus Monkey)

Gene Symbol

LAG3

UniProt

Additional LAG-3 Products

Product Documents for Cynomolgus Monkey LAG-3 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Cynomolgus Monkey LAG-3 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...